Showing 241-250 of 7665 results for "".
- Study: Melanoma No Longer the Leading Cause of Skin Cancer Deathshttps://practicaldermatology.com/news/study-melanoma-no-longer-the-leading-cause-of-skin-cancer-deaths/2462062/Non-melanoma skin cancer (NMSC) is causing a greater number of global deaths than melanoma, according to a new study presented at the European Academy of Dermatology and Venerology (EADV) Congress 2023 in Berlin, Germany. Researchers also believe that NMSC is underreported and that the true impact…
- Incyte and Mandy Moore Partner to Empower People with AD in New Campaignhttps://practicaldermatology.com/news/incyte-and-mandy-moore-partner-to-empower-people-with-ad-in-new-campaign/2462060/Actress, singer and songwriter Mandy Moore is partnering with Incyte on Moments of Clarity, an educational initiative highlighting the authentic stories of people living with mild to moderate atopic dermatitis (AD). As someone who also lives with eczema, Moore understands the challenges of the co…
- Positive Phase 2a Data Shown for MC2-32, a Novel HSP90 Inhibitor in HShttps://practicaldermatology.com/news/positive-phase-2a-data-shown-for-mc2-32-a-novel-hsp90-inhibitor-in-hs/2462058/MC2-32 (previously RGRN-305), a first-in-class, oral therapy HSP90 inhibitor, performed well in Hidradenitis Suppurativa (HS), according to Phase 2a results presented during a late-breaking session at the European Academy of Dermatology and Venereology (EADV) Annual Meeting in Berlin. The single c…
- AbbVie’s JAK inhibitor RINVOQ "Measures Up" in ADhttps://practicaldermatology.com/news/abbvies-jak-inhibitor-rinvoq-measures-up-in-ad/2462057/New Phase 3 research supports the long-term efficacy and safety of RINVOQ (upadacitinib) in moderate to severe atopic dermatitis (AD), according to data analyses from the Measure Up 1, Measure Up 2, and AD Up studies presented at the European Academy of Dermatology and Venereology (EADV) Congress i…
- Drs. Jedd D. Wolchok and Lisa Newman Elected to National Academy of Medicinehttps://practicaldermatology.com/news/drs-jedd-d-wolchok-lisa-newman-elected-to-national-academy-of-medicine/2462055/Melanoma specialist Dr. Jedd D. Wolchok, the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, in partnership with NewYork-Presbyterian, and Dr. Lisa Newman, chief of the section of breast surgery at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell …
- Protagonist Therapeutics JNJ-2113 Update: IL23-Blocker Advances Into Multiple Clinical Development Programs for PsO, UChttps://practicaldermatology.com/news/jnj-2113-update-il23-blocker-advances-into-multple-clinical-development-programs-for-pso-uc/2462054/Protagonist Therapeutics, Inc. will be eligible to receive $60 million in milestone payments in the fourth quarter for the advancement of JNJ-2113 (formerly known as PN-235) into multiple clinical development programs led by Janssen Biotech, Inc., a Johnson & Johnson company (Janssen), the Company'…
- Professor Alexander Egeberg Named Head of Global Medical Affairs at Leo Pharmahttps://practicaldermatology.com/news/professor-alexander-egeberg-named-will-head-of-global-medical-affairs-at-leo-pharma/2462050/Professor Alexander Egeberg is LEO Pharma’s new Vice President, Head of Global Medical Affairs. The announcement was made ahead of the upcoming 32nd European Academy of Dermatology and Venereology (EADV) Congress. Alexander Egeberg joins LEO Pharma from his role as professor of dermatology at the …
- DecisionDx-Melanoma Outperforms MSKCC Nomogram in Predicting Sentinel Lymph Node Positivity in Melanomahttps://practicaldermatology.com/news/decisiondx-melanoma-outperforms-mskcc-nomogram-in-predicting-sentinel-lymph-node-positivity-in-melanoma/2462044/Castle Biosciences, Inc.’s DecisionDx-Melanoma outperformed a nomogram developed at the Memorial Sloan Kettering Cancer Center (MSKCC) in predicting the risk of sentinel lymph node (SLN) positivity in patients with cutaneous melanoma (CM), according to a new study in Anticancer Research. The study…
- Dermavant Appoints John Darden as New Head of Marketinghttps://practicaldermatology.com/news/dermavant-appoints-john-darden-as-new-head-of-marketing/2462043/John Darden is the new Vice President of Marketing at Dermavant Sciences. In his most recent role as Executive Director, Marketing and U.S. Brand Lead, Mr. Darden directed the healthcare professional, consumer, and field-based marketing strategies for Otezla (apremilast) tablet. “I am proud to jo…
- Regenerative Medicine Breakthrough: Researchers Create BioPrinted Full Thickness Skinhttps://practicaldermatology.com/news/regenerative-medicine-breakthrough-researchers-create-bioprinted-full-thickness-skin/2462041/New bioprinted skin may accelerate wound healing, support healthy extracellular matrix remodeling, and aid in complete wound recovery, according to research out of the Wake Forest Institute for Regenerative Medicine (WFIRM). Available grafts are often temporary, or if permanent, have only some of…